在索兰班p.(Arg14del) 阳性个体中确定心力衰竭结果的预测因素
Myrthe Y C van der Heide1, Tom E Verstraelen1, Remco de Brouwer2
1Heart Center, Department of Cardiology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
JACC. Heart failure
|August 9, 2025
概括
这项研究确定了具有索兰班 (PLN) p.(Arg14del) 突变的个体心力衰竭结果的关键临床预测因子,有助于新兴基因疗法风险分层.
科学领域:
- 心血管遗传学 心血管遗传学
- 心脏衰竭病理生理学 病理生理学
- 遗传医学是一种遗传医学.
背景情况:
- 索兰班 (PLN) p.(Arg14del) 突变给心肌病和心力衰竭带来高风险.
- 目前的心力衰竭治疗对于PLN p.
- 鉴定风险患者对于推进遗传性心肌病的基因疗法至关重要.
研究的目的:
- 确定 PLN p.(Arg14del) 突变的个体心力衰竭结果的临床预测因素.
- 改进遗传性心肌病的风险预测模型.
- 为指导患者选择新型遗传疗法.
主要方法:
- 分析了PLN/ACM注册表中904个个人的数据.
- 使用最小绝对收缩和选择运算符 (LASSO) 考克斯回归.
- 主要终点:心力衰竭住院,设备植入,移植或死亡的复合.
主要成果:
- 116名参与者 (13%) 在中位数5.4年的随访期间经历了一次主要终点事件.
- 确定了重要的预测因素:左心室喷射率降低,低压心电图,以及基线时NYHA功能类≥II.
- 这些预测因素在所有LASSO回归模型中仍然显著.
结论:
- 左心室喷射分数,低压心电图和NYHA等级≥II是PLN p.
- 这些发现增强了PLN p. ((Arg14del) 相关心肌病患者的风险分层.
- 准确的风险预测对于及时应用先进的基因疗法至关重要.
相关概念视频
Heart Failure II: Pathophysiology
41
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
41
Pathophysiology of Heart Failure
1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
Heart Failure IV: Classification and Diagnostic Evaluation
32
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
32
Heart Failure I: Introduction
55
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
55
Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Cardiomyopathy II: Dilated Cardiomyopathy
22
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
22


